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The importance of paradigms for guiding scientific research is explained with reference to
the seminal work of Karl Popper andThomas Kuhn. A prevalent paradigm, followed for more
than a decade in HIV-1 vaccine research, which gave rise to the strategy known as structure-
based reverse vaccinology is described in detail. Several reasons why this paradigm did
not allow the development of an effective HIV-1 vaccine are analyzed. A major reason is
the belief shared by many vaccinologists that antibodies possess a narrow specificity for a
single epitope and are not polyspecific for a diverse group of potential epitopes. When this
belief is abandoned, it becomes obvious that the one particular epitope structure observed
during the crystallographic analysis of a neutralizing antibody–antigen complex does not
necessarily reveal, which immunogenic structure should be used to elicit the same type
of neutralizing antibody. In the physical sciences, scientific explanations are usually pre-
sented as logical deductions derived from a relevant law of nature together with certain
initial conditions. In immunology, causal explanations in terms of a single cause acting
according to a law of nature are not possible because numerous factors always play a role
in bringing about an effect.The implications of this state of affairs for the rational design of
HIV vaccines are outlined. An alternative approach to obtain useful scientific understanding
consists in intervening empirically in the immune system and it is suggested that manip-
ulating the system experimentally is needed to learn to control it and achieve protective
immunity by vaccination.
Keywords: structure-based reverse vaccinology, HIV-1 vaccines, antibody polyspecificity, paradigm, immunological
explanations
“It makes no sense to do the same thing over and over again
and expect a different result.”
Albert Einstein
INTRODUCTION
The development of science is promoted when scientists adhere
to so-called paradigms that correspond to theoretical presuppo-
sitions and assumptions that guide the lines of investigation they
pursue. When trying to solve a particular scientific puzzle, for
instance how to develop an effective HIV-1 vaccine, the para-
digm will also commit scientists to using particular experimental
approaches and tools believed to be essential for finding a solution
to the problem.
The importance of paradigms in guiding scientific research was
proposed by Thomas Kuhn (1) in his influential book “The Struc-
ture of Scientific Revolutions” published in 1962. Unfortunately, he
never clearly defined the concept of paradigm and he used the
term in various ways, for instance, to refer to a collection of pro-
cedures and ideas that instruct scientists what to believe and how
to work (2). Kuhn later conceded that the term paradigm had
become hopelessly overused because it came to signify virtually
any dominant idea that binds a scientific community together. He
subsequently recommended that paradigm be replaced by exem-
plar to mean exemplary instances of successful puzzle-solutions
for scientific problems. An exemplar captures the way in which a
theory or model is believed to solve a problem while at the same
time defining, which new problems could be addressed in a similar
way. However, the term paradigm was never abandoned.
Kuhn argued that when scientists in the course of their work
obtain results that contradict the theory or hypothesis that gave
rise to a paradigm, they do not conclude that the paradigm has
been refuted and must be abandoned. Scientists, therefore, do not
follow the injunction of Karl Popper that their aim should be to try
to disprove or falsify their theories rather than prove them. Pop-
per maintained that observations are never able to prove a theory
but can only sometimes logically refute a mistaken theory (3). He
argued that when scientists obtain reproducible results that are at
odds with their working hypothesis, they are logically obliged to
accept that the hypothesis has been falsified and they should there-
fore abandon it (4). Kuhn disagreed and claimed that this is not
the way scientists behave because their main commitment is not
to test or seek to confirm the implicit theories and hypotheses that
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underlie the paradigms they adhere to. Scientists in fact tend to
ignore anomalous results and will devise new ad hoc hypotheses in
an effort to explain away apparent contradictions between theory
and experimental observations. Kuhn further claimed that science
can make progress only if scientific communities remain commit-
ted to their shared theoretical beliefs and experimental techniques
and do not abandon a paradigm or hypothesis as soon as incom-
patible results are obtained (5). Only if troublesome anomalies
keep accumulating over many years may scientists eventually start
questioning their presuppositions and lose their confidence in a
given paradigm. This could then usher a scientific revolution that
occurs when a paradigm is superseded by a new one and gives rise
to a paradigm shift. Periods of so-called normal science are then
replaced by a short period of revolutionary science (1).
In HIV vaccine research, there is evidence that several preva-
lent paradigms have not helped the development of an effective
vaccine (6–8). One such paradigm, which gave rise to the strategy
known as structure-based reverse vaccinology (RV) (9) was pur-
sued vigorously for more than a decade although it did not lead
to the development of an effective HIV-1 vaccine. The theoretical
underpinnings of this paradigm have been discussed previously
because they illustrate the need for investigators to question the
implicit underlying assumptions that make them pursue unfruit-
ful lines of investigation (10, 11). Only when the presuppositions
or hypotheses that gave rise to unsuccessful paradigms are shown
to be invalid will investigators become aware that a paradigm shift
is required in a particular scientific field (8).
STRUCTURE-BASED RV PARADIGM IN HIV-1 VACCINE
RESEARCH
The approach known as RV was introduced in the field of bacte-
rial vaccines by Rino Rappuoli (12, 13) and refers to the strategy
of predicting potential vaccine immunogens using bioinformat-
ics analyses of entire bacterial genomes in order to identify all
the surface-exposed proteins that a bacterial pathogen is able to
express. The strategy is called RV because investigators operate
in a reverse manner, i.e., starting from the genome rather than
from the organism, to discover, which bacterial proteins should be
studied as potential vaccine immunogens. This allows hundreds of
bacterial proteins to be identified as candidate immunogens even
when bacteria cannot be cultivated and bacterial extracts cannot
therefore be fractionated to establish empirically which proteins
are able to induce a protective immune response.
In virology, RV has a different meaning and refers to a strategy,
which attempts to generate a vaccine from a knowledge of pro-
tective antibodies (Abs) rather than from the usual reverse task
of generating such Abs by immunization with a vaccine (9, 14).
It was suggested that effective vaccine immunogens might be dis-
covered by exploring the interaction of anti-HIV-1 neutralizing
(n)Abs with HIV-1 envelope (Env) spikes, using X-ray crystallog-
raphy of Env–Ab complexes. This expectation was based on the
assumption that once the 3D structure of a broadly neutralizing
monoclonal antibody (bnMab) bound to an Env epitope had been
elucidated, it would be possible to use the bnMab as a template to
reconstruct its complementary epitope outside the context of the
natural Env antigen, using structure-based design. It was further
hypothesized that this reconstructed epitope designed to fit the
bnMab would possess the immunogenic capacity of inducing a
polyclonal Ab response with the same neutralizing capacity as the
bnAb used as template. The assumption was that if an HIV-1
epitope is able to bind an Ab, it will also possess the immuno-
genic capacity to elicit the same type of Ab in an immunized host.
That this is not necessarily the case, however, is demonstrated by
the common observation that when a peptide fragment of a pro-
tein is able to bind Abs raised against the protein, the peptide
will frequently be unable to elicit Abs that react with the native
protein (15).
Since the RV approach used to develop bacterial vaccines has
been highly successful (13) whereas, the RV approach used in the
HIV-1 vaccine field has failed so far (10, 16, 17) it has been sug-
gested that the two approaches should be clearly differentiated
and could be called genome-based RV and structure-based RV,
respectively (18).
UNWARRANTED ASSUMPTIONS OF THE
STRUCTURE-BASED RV PARADIGM
The structure-based RV approach suffers from several unwar-
ranted expectations that jeopardized the ability of developing an
effective HIV-1 vaccine. It did not clearly distinguishing between
antigenicity and immunogenicity (12, 19) and analyzed epitopes
in antigens and paratopes in Abs solely in terms of which amino
acids in the two partners made contact with each other (20). As a
result, little attention was given to the fact that the binding activ-
ity of an Ab often depends on structural features distant from the
paratope itself (21, 22) and that residues in the antigen that are not
in contact with the paratope may nevertheless be able to affect the
binding activity and the immunogenic activity of epitopes (23, 24).
Such findings confirm an insight reached years ago that paratopes
and epitopes defined in terms of contact residues often differ from
the binding sites defined in functional assays (25). The structures
visualized in Ab-antigen complexes also tend to differ from the
structures of the binding sites in the free molecules, before they
have been altered by the mutual adaptation and induced fit that
occur when the two partners interact (26, 27). This means that the
particular antigenic structure revealed in an Ab–antigen complex
does not necessarily correspond to the immunogenic structure that
was recognized by B-cell receptors (BCRs) during the immuniza-
tion process and which therefore is often presumed to be needed
in the vaccine immunogen.
In an earlier review (11), more than 50 original science publica-
tions were mentioned, which attempted to reconstruct active HIV-
1 epitopes using conformational constraints, protein scaffolds, and
other structure-based engineering approaches. Although some
of the engineered epitopes possessed increased antigenicity and
reacted better with bnMabs, none of them were found to be effec-
tive vaccine immunogens, illustrating the shortcomings of the
structure-based RV approach (28–32).
OVERLOOKING THE NEED FOR ANTIBODY AFFINITY
MATURATION TO OBTAIN EFFECTIVE ANTI HIV-1
NEUTRALIZING Abs
Another unjustified hypothesis of the structure-based RV
approach was that the HIV-1 epitopes recognized by the matured
bnMabs that are present in HIV-1 infected individuals after a
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lengthy process of Ab affinity maturation will be able to trigger a
protective immune response in naïve individuals. However, stud-
ies involving the deep sequencing of all the HIV-1 Abs present
in the serum of infected individuals demonstrated that the ini-
tial immunogen triggering the Ab affinity maturation process that
leads to neutralizing Abs usually recognizes a germline version of
BCRs that differs considerably from the BCRs corresponding to
mature bnAbs (33, 34). This means that the epitopes engineered
by structure-based RV to mimic HIV-1 epitopes recognized by
mature bnMabs are unlikely to be effective vaccine immunogens
because they are mostly unable to recognize the germline BCRs
present in naïve individuals (35–38).
The extent of affinity maturation observed in HIV-1 bnAbs
is much more extensive than the 5–10% mutation frequency in
the Ab hypervariable regions observed with Abs directed to other
viruses (37–39) and this characteristic feature of HIV-1 bnAbs
together with the enormous antigenic variability of the virus
explains why the structure-based RV approach in the case of HIV-
1 presented unsurmountable challenges compared to other viral
vaccines (36, 40, 41). HIV-1 elicits bnAbs only in a minority of
infected individuals after several years of infection and attempts
are currently made to unravel the mutational pathway that leads
from germline BCR ancestors to mature Abs (42). The goal is to
identify various immunogens capable of stimulating successive
B-cell responses through multiple rounds of antibody maturation
processes (43, 44). This is clearly no mean task since large numbers
of maturation pathways are likely to exist (45–47).
Current attempts to modify Env epitopes so that they are able
to bind germline BCRs or maturation intermediates depart from
the original structure-based RV paradigm because they no longer
attempt to directly transform epitopes of known structure recog-
nized by mature bnMabs into immunogens capable of eliciting
similar bnAbs (46–48). This new approach represents a new par-
adigm based on the germline/maturation hypothesis (34), which
assumes that it may be possible to discover effective HIV-1 vaccine
immunogens that bind putative germline antibody predecessors
of known HIV-1 bnAbs although they do not bind the highly
somatically mutated bnAbs themselves (49).
In recent years, increasing numbers of bnMabs have been iso-
lated from HIV-1 infected individuals (50–52) and it has been
suggested that these Mabs provide valuable molecular information
that could inform HIV-1 vaccine design (53, 54). Such bnMabs
may be of value for passive immunotherapy since they could pro-
vide sterilizing immunity to humans and non-human primates
when they are administered prior to viral challenge (55, 56). How-
ever, their usefulness does not at present extend to the vaccine field
since we have no idea how Abs that possess the protective capacity
of such bnMabs can be induced by vaccination (11). There is also
considerable evidence that a protective immune response requires
the combined neutralizing activities of several Abs that target dif-
ferent non-overlapping HIV-1 Env epitopes (57) as well as Abs that
act in synergy (58–60). What may be required, therefore, is to find
immunogens able to elicit classical types of protective, polyclonal
immune responses rather than elusive immunogens that would
elicit single Ab specificities endowed with the exceptional neutral-
izing capacity of individual bnMabs such as the well-studied b12,
VRC01, PG9, or PG16 bnMabs (61–63).
RELIANCE ON REDUCTIONIST THINKING: ANOTHER PITFALL
OF THE STRUCTURE-BASED RV PARADIGM
Another pitfall of the structure-based RV paradigm is its reliance
on reductionist thinking (11). Reductionism has been preva-
lent in molecular biology for half a century and is still popular
today because it has been very successful for dissecting biologi-
cal systems into their constituent parts (64, 65). The reductionist
mindset made immunologists accept that the biological activi-
ties of Abs could be explained by their 3D structures and that
the immunogenic potential of a viral epitope could be deduced
from its antigenic properties. Biological immunogenicity was
thereby reduced to chemical antigenicity, which is a variation of
the claim that biology can be reduced to chemistry (66). Such
a claim fails to recognize that the protection achieved by vac-
cination is a biological phenomenon that has meaning only in
the context of an entire organism since organs, tissues, or mol-
ecules cannot be vaccinated. Protection always results from a
complex network of dynamic interactions between pathogen, host,
and immune system and it cannot be satisfactorily understood
when innumerable, individual molecular interactions are analyzed
separately.
The use of Mabs also introduces a reductionist bias in the analy-
sis of protein antigenicity and immunogenicity because it leads
investigators to focus on artificial boundaries between overlapping
epitopes and to ignore the fact that the apparent immunological
specificity of a Mab very much depends on the selection process
that was used to obtain it. Since a Mab is always polyspecific,
the fact that it binds, for instance, to one particular peptide of
the membrane proximate external region (MPER) of HIV-1 gp41
simply reflects the fact that the Mab was selected for its ability to
bind to that peptide. Such a Mab may, however, recognize better a
more complex epitope of gp41 that could actually have been the
immunogen that gave rise to the Mab. If it is assumed that the
Mab was elicited by the linear MPER peptide epitope because it
binds to it, this may induce investigators to only investigate pep-
tides as possible vaccine immunogens, a choice, which is likely to
be self-defeating (15, 67).
STRUCTURE-BASED RV PARADIGM SUFFERS FROM
ANOTHER MAJOR MISGUIDED ASSUMPTION, NAMELY AN
OUTDATED NOTION OF Ab SPECIFICITY
According to this view, which is usually not explicitly acknowl-
edged, a Mab that would bind for instance to an epitope on the
HIV-1 Env surface is believed to be able to recognize only a single
defined target area (the so-called complementary epitope of the
Mab) corresponding to the surface residues found to be in con-
tact with paratope residues in the Ab–antigen complex. Although
the belief that Mabs are monospecific for a single epitope is no
longer held and was shown to be invalid already 30 years ago
(68–74) many vaccinologists have been slow to accept that there
is no single intrinsic or specific epitope for any Ab but only a
diverse group of potential epitopes able to bind to it with various
degrees of fit (10, 75, 76). It seems that the failure to recognize
that Abs are always polyspecific and possess considerable plastic-
ity, promiscuity, degeneracy, and cross-reactive potential has made
the structure-based RV approach appear more plausible to many
investigators (10).
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It is now well-established that most Abs derived from Ab
germline genes and expressed before any antigenic stimulation
are highly polyreactive and react with a wide variety of autoanti-
gens such as DNA, cytoskeleton proteins, nuclear antigens, and
carbohydrates as well as numerous bacterial and viral antigens
(70, 77–81). The various mechanisms that allow a polyspecific Ab
to recognize a multiplicity of epitopes and antigens have been elu-
cidated (82). Once investigators realize that the epitope structure
observed in a bnMab–HIV-1 Env complex is only one of the many
epitopes that could be accommodated by what is always a poly-
specific Ab, they have no difficulty to accept that any one of these
epitopes could correspond to the immunogen that gave rise to
the Mab. They will then no longer assume that the one epitope
structure observed in the crystallographic analysis of an antigen
complex must necessarily reveal, which immunogenic structure
should be used to elicit such a bnAb (10).
Furthermore, the fact that Abs are not only polyspecific but
are also heterospecific, i.e., able to react more strongly with other
antigens than with the immunogen used for eliciting the Ab, also
helps to clarify why antigenic and immunogenic properties are not
always simultaneously present in the same region of a protein (76).
The immunogenic capacity of an epitope to induce heterospecific
Abs that do not react with the protein used for immunization
demonstrates that immunogenicity need not be accompanied by
an antigenic reactivity that enables the epitope to bind to the
induced Abs. Similarly, the antigenic reactivity of a viral protein
revealed by its ability to bind a given polyspecific Ab is also not
necessarily accompanied by an immunogenic capacity to induce
that same Ab in a particular immune system (76).
Although the advent of Mabs has completely transformed
our ability to dissect immune responses to proteins, their uti-
lization has also introduced a bias in the antigenic analysis of
viruses because investigators tend to focus on artificial boundaries
between overlapping epitopes and overlook the fact that the sur-
face of a protein is an antigenic and functional continuum (83).
When an nMab has been isolated, it tends to become associated
with a unique, discrete epitope, which leads to the expectation
that a vaccine containing this epitope will induce similar nAbs.
However, most protective immune responses are polyclonal and
involve the collective and synergistic neutralizing activities of Abs
directed to different epitopes (61). When the therapeutic effi-
cacy of mixtures of HIV-1 neutralizing Mabs was tested in HIV-1
infected humanized mice, it was found that mixtures of five Mabs
were more effective than single Mabs or mixtures of three Mabs
(84). Mixtures of five Abs suppressed viral loads below the level
of detection and also failed to select escape viral mutants. How-
ever, chronically HIV-1 infected humans from whom bnAbs were
isolated do not appear to benefit from such Abs for controlling
virus replication (17, 85, 86), nor do HIV-1 infected long-term
progressors compared to non-progressors (87). The role of Abs
in controlling chronic HIV-1 infection therefore remains an issue
that should be further investigated.
Many unsuccessful attempts have been made to elicit by immu-
nization bnAbs similar to potent bnMabs isolated from HIV-1
infected individuals (17, 88). The past research emphasis on unrav-
eling the neutralization mechanisms of individual bnMabs did
not help because it did not provide any information on which
immunogens were capable of eliciting the different types of bnAbs.
The poor success rate so far in discovering even one such effective
HIV-1 vaccine immunogen by structure-based RV is certainly a
cause of concern. As discussed elsewhere (8), there is a clear need to
study new vaccine immunogens and new methods to induce strong
mucosal antibody responses using for instance specific adjuvants.
Other markers than viral load and CD4 T cell counts for assessing
vaccine efficacy should also be investigated (8).
It is nowadays commonly claimed that rational design offers
the best prospects for developing an HIV-1 vaccine and that this
approach is superior to the empirical screening and trial-and-error
strategies used in the past. When it is claimed that “rational design
represents the only approach that can elevate vaccine research from
an empirical exercise to a scientific discipline” (89), the essential
contribution of empirical trials to vaccine development is actu-
ally denigrated as if trial-and-error experimentation were not an
entirely rational enterprise (10, 11, 19). When authors discuss
the rational design of an HIV-1 vaccine (90, 91) they only refer
to studies that improve the degree of complementarity in a sin-
gle epitope–Mab pair and they do not clarify how an improved
antigen could actually be “designed” to also become an immuno-
gen capable of inducing protective Abs. Optimizing the binding
activity of a viral antigen by structure-based design using a single
Mab as a template is certainly feasible but this is not equivalent to
immunogen design, which requires the intentional optimization
of numerous factors extrinsic to the epitope–paratope recogni-
tion such as the various cellular and regulatory mechanisms of
the host that exist only in the context of the vaccinated host
and control the generation of neutralizing Abs (11, 92). Anti-
gen design is simply masquerading as immunogen design when
it is assumed that an improved viral antigen will also be an effec-
tive vaccine immunogen capable of inducing a protective immune
response. The so-called rational design of vaccine immunogens
by mimicking the rational approach used in drug design (10, 93,
94) is not feasible without extensive empirical clinical trials of
vaccine candidates and to suggest otherwise contradicts the well-
established empirical nature of vaccine science. The concern that
too much funding may be diverted to empirical clinical trials at the
expense of basic structure-based HIV vaccine research (95) seems
unwarranted since the lion share of current funding is devoted to
structural studies whereas, the required small scale clinical trials
based on innovative paradigm concepts remain poorly funded (8).
CAUSES, EXPLANATIONS, AND UNDERSTANDING IN
VACCINOLOGY
The selection of a paradigm to guide the empirical search for an
HIV-1 vaccine always depends on framing hypotheses about causal
mechanisms, which could provide a plausible explanation for a
possible successful vaccine. Most scientific explanations take the
form of a causal mechanistic explanation,which means that causes,
explanations and understanding are usually intimately linked (96,
97). It is relevant therefore to analyze how these three terms are
used in vaccinology.
In the physical sciences, explanations are usually presented as
logical deductions derived from one or a few relevant laws of
nature, together with certain initial conditions. However, this is
not feasible in the biological sciences because of the absence of
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universal biological laws (11, 98). Since the probability of a bio-
logical event is always affected by a very large number of causal
factors, causal links become diluted and it is usually not possible to
provide an explanation in vaccinology in terms of a single cause.
The reductionist dissection of the immune system into its com-
ponents severs the dynamic connections that link the parts of
a biological complex system in a functionally integrated manner.
This allows any level in the resulting biological complexity to be the
starting point of a causal analysis, provided a certain state of affairs
is considered to be in need of an explanation. As a result, explana-
tions are usually framed in terms of a complex type of probabilistic
causality that attempts to take into account the numerous factors
that together contribute to an effect in a given biological context.
This means that the classical notion of causality is of limited value
for providing explanations in immunology (11, 96). The contri-
bution of one causal factor in a complex multicausal biological
system can actually only be investigated by altering that factor
experimentally and assessing whether the observed effect is then
no longer the same in a given context (94). This has led to the
suggestion that many biological phenomena may be too complex
to be comprehended or explained by human intelligence (99).
Attempts to achieve understanding in immunology often start
with information about observed effects and by an awareness
that certain phenomena share underlying similarities, which then
leads one to propose a theory or hypothetical model to explain
them. The structure-based RV paradigm is one such model, which
assumes that bnMabs that are isolated from HIV-1 infected indi-
viduals and recognize particular Env epitopes are likely to have
been elicited by these epitopes. When the model was tested by
assessing the immunogenicity of the epitopes recognized by dif-
ferent bnMabs, it was found that the results did not fit the model
and that no bnAbs were elicited (29, 30, 100). This should remind
us that a proposed explanatory model does not predict the data
to which it is fitted since the model is actually chosen to fit the
data and it makes no sense to fit what one wants to explain (101).
Understanding consists of knowledge about relations of depen-
dence and should make it possible to derive inferences about the
consequences of our interventions and give us an ability to predict
and control phenomena. Unfortunately, it seems that scientists
tend to overestimate the detail and depth of their understand-
ing, which often consists of nothing more than an informed guess
about the future prospects of their scientific work. This leads to
a frame of mind that has been called an “illusion of depth of
understanding in science” (102). In the absence of experimental
data that back their explanatory model or paradigm, scientists do
not choose which theory to accept but choose which theory they
are actually going to work with. Scientists are then driven by the
promise of future understanding rather than by past convincing
explanatory evidence and such an expectation is easily influenced
by wishful thinking about their pet theories (102).
Since understanding a phenomenon is ultimately displayed by:
(1) making right predictions, (2) successfully intervening in a sys-
tem, and (3) answering explanation-seeking questions about it,
the inability to do any of these things is a clear indication that
alternative explanatory hypotheses and paradigms are required.
As far as HIV-1 vaccines are concerned, our ignorance of why all
Env immunogens investigated so far have been unable to induce
adequate levels of potent protective Abs is a clear indication that
we do not understand the complex mechanisms that are involved
in achieving protective immunity against HIV-1.
Although the complexity of the immune system may prevent
us from identifying all its internal regulatory mechanisms, it is
by comparing the various ways of manipulating the system using
empirical experimentation that we may eventually control it and
achieve protective immunity by vaccination (11).
Empirical, scientific knowledge is based on experimental and
observational facts and on the rule that “nothing trumps experi-
ence.” However, it has been argued that empirical evidence only
allows scientists to draw plausible but tentative conclusions when
the obtained results make it possible to successfully control and
manipulate the experimental system under investigation (103,
104). If this does not happen, empiricism dictates that we should
investigate additional constituents of the complex biological sys-
tems we study until we improve our ability to predict the results
of our experimental interventions. It is indeed the ability of inves-
tigators to successfully intervene in a material system that gives
them the knowledge needed to manipulate and control it.
Since the aim of biologists is both to explain and control biolog-
ical phenomena, explaining goes hand-in-hand with intervening
and it has been suggested that “explanations in biology are always
obtained through direct intervention on models of the phenom-
enon to be explained” (105). It is important to recognize that
such a view is at odds with the widespread expectation that we
will succeed in developing an effective HIV-1 vaccine only when
we have significantly increased our general knowledge of basic
immunology and of HIV-1 antigenic structure (11). This means
that we need to interfere with the material world in order to obtain
empirical knowledge about it and that our scientific understanding
increases when we are able to successfully manipulate the system
we investigate (106).
CONCLUSION
There is evidence that the popular structure-based RV paradigm
used in HIV-1 vaccine research has not been helpful for develop-
ing an effective HIV-1 vaccine. Some of the reasons for this lack
of success are summarized, one of them being the failure to recog-
nize that all Abs as well as bnMabs isolated from HIV-1 infected
individuals are always polyspecific and able to bind to a variety of
related and unrelated epitopes. Since the epitope structure iden-
tified by X-ray crystallography of a bnMab–HIV-1 Env complex
is only one of several epitopes that could be accommodated by
the Mab, there is no reason to assume that this epitope of known
structure must correspond to the immunogen that elicited the
antibody.
Recently, one of the major groups committed to the structure-
based RV paradigm reported a study of bnMabs that recognize
a high-mannose epitope patch centered on the N 332 residue on
HIV Env. They demonstrated that these Abs actually did not have
a single defined target point at N 332 but were in fact polyspe-
cific and able to bind various glycan patches as well as a glycan
site located at N334 (107). For the first time, these authors admit-
ted that antibody polyspecificity was a relevant concept in HIV-1
vaccine research and they claimed that their results represent an
extension of the concept of antibody promiscuity and degeneracy
www.frontiersin.org November 2014 | Volume 5 | Article 593 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Van Regenmortel Outdated notion of antibody specificity
that has been widely accepted in immunology for many years (10,
68, 73–75). They also concluded that polyclonal Abs are more
effective for neutralizing viruses than individual Mabs and that
the polyspecificity of vaccine-induced Abs should receive increased
attention. The new insights arrived at by these authors might in
time alter the expectations of the proponents of the structure-
based RV paradigm and diminish their reliance on structural data
derived from the study of individual bnMabs.
The structure-based RV paradigm has been followed by sev-
eral large networks of investigators who operate under the strong
leadership of principal investigators (108). This situation leads
to considerable built-in inertia and does not encourage funding
agencies to back large numbers of high-risk projects based on
alternative innovative paradigms that could diversify the vaccine
strategies that are investigated (8, 108). These issues are currently
receiving increased attention and it is hoped that this will in due
course lead to increased funding for new original science based on
novel paradigms and that it will stimulate a rigorous evaluation of
existing HIV vaccine programs (108).
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